Citius Pharmac Dl Stock Retained Earnings
| 47N Stock | EUR 3.29 0.00 0.00% |
CITIUS PHARMAC DL fundamentals help investors to digest information that contributes to CITIUS PHARMAC's financial success or failures. It also enables traders to predict the movement of CITIUS Stock. The fundamental analysis module provides a way to measure CITIUS PHARMAC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CITIUS PHARMAC stock.
CITIUS |
CITIUS PHARMAC DL Company Retained Earnings Analysis
CITIUS PHARMAC's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, CITIUS PHARMAC DL has a Retained Earnings of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The retained earnings for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
CITIUS Fundamentals
| Return On Equity | -0.28 | |||
| Return On Asset | -0.16 | |||
| Shares Outstanding | 146.21 M | |||
| Shares Owned By Insiders | 8.42 % | |||
| Shares Owned By Institutions | 11.00 % | |||
| EBITDA | (33.31 M) | |||
| Net Income | (23.66 M) | |||
| Cash And Equivalents | 115.66 M | |||
| Cash Per Share | 0.79 X | |||
| Total Debt | 1.06 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 32.48 X | |||
| Book Value Per Share | 0.70 X | |||
| Cash Flow From Operations | (22.02 M) | |||
| Earnings Per Share | (0.19) X | |||
| Target Price | 7.0 | |||
| Number Of Employees | 21 | |||
| Beta | 1.2 | |||
| Market Capitalization | 186.2 M |
About CITIUS PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CITIUS PHARMAC DL's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CITIUS PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CITIUS PHARMAC DL based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in CITIUS Stock
CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.